Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
PUR-WASH vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.
PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.
Sterile irrigation of body cavities, wounds, and surgical sites,Cleansing of wounds and burns,Rinsing of instruments and equipment,Hydration of tissues during surgical procedures
Peritoneal dialysis for patients with end-stage renal disease,Correction of fluid and electrolyte imbalances,Correction of metabolic acidosis
Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.
Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.
Terminal elimination half-life is 12-18 hours (mean 15 h). In patients with moderate renal impairment (Cr Cl 30-50 m L/min), half-life may extend to 24-30 hours; severe impairment (Cr Cl <30 m L/min) may prolong to >40 hours, requiring dose adjustment.
Terminal elimination half-life is approximately 0.5–1 hour in patients with normal renal function. In end-stage renal disease (ESRD), half-life extends to 6–8 hours, requiring dose adjustment.
PUR-WASH is not metabolized; it is absorbed and excreted unchanged by the kidneys if administered intravenously or absorbed from wounds. When used topically or for irrigation, minimal systemic absorption occurs.
Bicarbonate and lactate are metabolized in the liver and kidneys. Lactate is converted to bicarbonate via hepatic gluconeogenesis and the Cori cycle.
Primarily renal excretion of unchanged drug (85-90%), with 10-15% fecal elimination via biliary secretion.
Renal: 100% (proximal tubular secretion and glomerular filtration). Biliary/fecal: negligible (<1%).
Approximately 98% bound primarily to albumin; minor binding to alpha-1-acid glycoprotein (AAG).
Approximately 10–20% bound to albumin. Binding is low and clinically insignificant.
Vd = 0.3-0.5 L/kg, indicating moderate distribution into total body water; higher Vd observed in obesity (0.6 L/kg) due to lipophilicity.
Volume of distribution is 0.2–0.3 L/kg (10–20 L in adults), approximating extracellular fluid volume. This small Vd is consistent with limited tissue penetration.
Oral: 95-100% (first-pass metabolism negligible); Intramuscular: 100%; Subcutaneous: 90-95% (site-dependent).
Intravenous: 100% (only route of administration).
No systemic absorption; not applicable.
Contraindicated in severe renal impairment (e GFR <30 m L/min/1.73m²) due to risk of hyperphosphatemia and hyperkalemia. In mild to moderate impairment (e GFR 30-89): reduce dose by 25-50% and monitor serum potassium and phosphate levels.
No systemic absorption; not applicable.
No specific dose adjustment recommended for Child-Pugh class A or B. For Child-Pugh class C: use with caution and consider reducing dose by 25% due to potential for altered phosphate metabolism and encephalopathy risk.
No systemic absorption; use as directed for wound irrigation per local protocol.
Dose based on body weight: 1-2 mmol/kg/day of potassium phosphate intravenously as part of parenteral nutrition, with infusion rate not exceeding 0.5 mmol/kg/hour. Maximum daily dose: 4 mmol/kg.
No systemic absorption; use as directed for wound irrigation per local protocol.
Start at lower end of dosage range (e.g., 20-30 mmol/day) due to age-related renal function decline. Monitor renal function and serum electrolytes closely; adjust dose based on creatinine clearance.
None
None.
For external use only. Not for injection. Use only if solution is clear and container undamaged. Discard unused portion. Do not use for irrigation of closed cavities without adequate drainage. Monitor fluid and electrolyte balance when large volumes are used, especially in patients with renal impairment or cardiac failure. Prolonged contact with tissues may cause maceration.
Peritonitis risk,Catheter-related infections,Fluid and electrolyte disturbances,Metabolic alkalosis (with high bicarbonate levels),Hypokalemia or hyperkalemia,Peritoneal membrane failure
Hypersensitivity to any component. Do not use for irrigation of body cavities where absorption may lead to fluid overload or electrolyte disturbances without appropriate monitoring. Not for intravascular or intrathecal use.
Hypersensitivity to any component,Pre-existing severe metabolic alkalosis,Documented peritoneal membrane failure,Abdominal or peritoneal defects (e.g., hernias, fistulas),Uncorrected mechanical defects in peritoneal cavity
None relevant as PUR-WASH is a topical irrigating solution with no systemic absorption.
No direct food interactions, but dietary intake of potassium, calcium, and phosphorus must be managed per clinical guidelines during CRRT. Avoid high-potassium foods (e.g., bananas, oranges, potatoes) unless potassium supplementation is adjusted accordingly.
PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly needed. No specific trimester risks have been identified.
No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or electrolyte imbalances may pose risks. First trimester: theoretical risk of teratogenicity only with severe maternal hyperphosphatemia. Second/third trimesters: risks include fetal hyperphosphatemia, hypocalcemia, and potential soft tissue calcification. Use only if clearly needed.
It is unknown whether PUR-WASH is excreted in human breast milk. The M/P ratio has not been determined. Caution is advised; consider the developmental and health benefits of breastfeeding along with the mother's clinical need.
Potassium phosphate is present in human milk at levels consistent with physiological requirements. Milk-to-plasma ratio not established. Exogenous phosphate is rapidly absorbed and may cause hyperphosphatemia in the infant at high maternal doses. Caution advised; monitor infant for signs of hyperphosphatemia (e.g., hypocalcemia, tetany).
No pharmacokinetic studies have been performed in pregnant women. Currently, no dose adjustment is recommended for PUR-WASH during pregnancy, but caution is warranted due to limited data.
Physiologic increase in plasma volume and glomerular filtration rate in pregnancy may increase phosphate clearance, potentially requiring higher doses to maintain therapeutic levels. However, individualize dosing based on serum phosphate monitoring. No standard dose modification; adjust per clinical response and lab values.
PUR-WASH is a sterile, preservative-free irrigating solution indicated for wound cleansing and debridement. Use at room temperature to avoid thermal injury. Do not use for prolonged irrigation of closed body cavities due to risk of fluid absorption. For external wounds only; not for injection or ophthalmic use.
PHOXILLUM B22K 4/0 is a bicarbonate-buffered, low-calcium dialysate for continuous renal replacement therapy (CRRT). Monitor serum potassium closely as it contains 4 m Eq/L K+, 0 m Eq/L Ca2+, and 22 m Eq/L bicarbonate. Use with caution in hyperkalemic patients; may require adjustment of potassium supplementation. Ensure adequate calcium replacement via separate infusion to avoid hypocalcemia. Verify compatibility with other IV fluids and medications administered through the CRRT circuit.
Do not ingest or inject this solution; it is for external wound cleaning only.,Discard any unused portion after opening; do not reuse or store opened bottles.,Do not apply heat or microwave the solution to avoid burns.,Use within 24 hours of opening to maintain sterility.,If irritation or infection occurs, stop use and consult your healthcare provider.
This solution is used only during continuous dialysis in the hospital setting; it is not for direct infusion into your vein.,Your healthcare team will monitor your blood potassium and calcium levels closely while you receive this treatment.,Do not eat or drink anything unless your doctor or nurse approves, as your diet may need to be adjusted.,Report any muscle cramps, tingling, or irregular heartbeat to your nurse immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about PUR-WASH vs PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER, answered by our medical review team.
PUR-WASH is a Irrigation Solution that works by PUR-WASH is a sterile, non-pyrogenic irrigating solution containing purified water and electrolytes. Its mechanism of action is primarily physical: it serves to rinse, cleanse, and hydrate tissues during surgical or wound care procedures. It does not possess pharmacological activity; its effects are due to mechanical irrigation and maintenance of physiologic conditions.. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is a Irrigation Solution that works by PHOXILLUM B22K 4/0 is a peritoneal dialysis solution containing bicarbonate/lactate as buffer. It corrects electrolyte imbalances, removes waste products (e.g., urea, creatinine) via diffusion and ultrafiltration across the peritoneal membrane. Bicarbonate helps correct metabolic acidosis.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between PUR-WASH and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER depend on the specific clinical indication. These are both Irrigation Solution agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of PUR-WASH is: Not applicable; PUR-WASH is a sterile irrigating solution for topical use only, not for systemic administration. No standard systemic dose.. The standard adult dose of PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is: Intravenous infusion of 4 mmol/kg potassium phosphate per 24 hours, administered at a rate not exceeding 10 mmol/hour as part of total parenteral nutrition; typical adult dose: 30-40 mmol potassium phosphate per day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between PUR-WASH and PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. PUR-WASH is classified as Category C. PUR-WASH has not been formally studied in pregnant women. Animal studies are lacking. There is no known teratogenic potential, but due to insufficient data, use only if clearly nee. PHOXILLUM B22K 4/0 IN PLASTIC CONTAINER is classified as Category C. No well-controlled studies in pregnant women. Animal reproduction studies not conducted. Potassium phosphate is essential for fetal development; however, hyperphosphatemia or elect. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.